Lukas Bajer
Overview
Explore the profile of Lukas Bajer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wohl P, Krausova A, Wohl P, Fabian O, Bajer L, Brezina J, et al.
World J Gastrointest Endosc
. 2024 Nov;
16(11):607-616.
PMID: 39600557
Background: Ulcerative colitis (UC) with concomitant primary sclerosing cholangitis (PSC) represents a distinct disease entity (PSC-UC). Mayo endoscopic subscore (MES) is a standard tool for assessing disease activity in UC...
2.
Bajer L, Ryou M, Thompson C, Drastich P
Clin Endosc
. 2024 Jan;
57(2):203-208.
PMID: 38229441
Background/aims: Upper gastrointestinal bleeding (UGIB) is the most common GI condition requiring hospitalization, and can be diagnosed by direct visualization. The present study aimed to evaluate the safety and feasibility...
3.
Coufal S, Kverka M, Kreisinger J, Thon T, Rob F, Kolar M, et al.
J Immunol Res
. 2023 Jun;
2023:1535484.
PMID: 37383609
Background: Tumor necrosis factor-alpha (TNF-) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long...
4.
Fabian O, Bajer L, Drastich P, Harant K, Sticova E, Daskova N, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298338
Inflammatory bowel diseases (IBD) are systemic immune-mediated conditions with predilection for the gastrointestinal tract and include Crohn's disease and ulcerative colitis. Despite the advances in the fields of basic and...
5.
Reiss Z, Rob F, Kolar M, Schierova D, Kreisinger J, Jackova Z, et al.
Front Cell Infect Microbiol
. 2023 Jan;
12:1064537.
PMID: 36704107
Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF...
6.
Rob F, Schierova D, Stehlikova Z, Kreisinger J, Roubalova R, Coufal S, et al.
PLoS One
. 2022 Dec;
17(12):e0277576.
PMID: 36584073
Background: Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the...
7.
Fabian O, Bajer L
World J Gastroenterol
. 2022 Oct;
28(36):5300-5312.
PMID: 36185628
Advances in diagnostics of inflammatory bowel diseases (IBD) and improved treatment strategies allowed the establishment of new therapeutic endpoints. Currently, it is desirable not only to cease clinical symptoms, but...
8.
Krausova A, Buresova P, Sarnova L, Oyman-Eyrilmez G, Skarda J, Wohl P, et al.
Mucosal Immunol
. 2022 Mar;
15(3):529.
PMID: 35301446
No abstract available.
9.
Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831411
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy...
10.
Krausova A, Buresova P, Sarnova L, Oyman-Eyrilmez G, Skarda J, Wohl P, et al.
Mucosal Immunol
. 2021 Oct;
15(2):373.
PMID: 34686840
No abstract available.